Edition:
United Kingdom

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

114.06USD
20 Apr 2018
Change (% chg)

$1.07 (+0.95%)
Prev Close
$112.99
Open
$113.13
Day's High
$114.69
Day's Low
$112.42
Volume
174,172
Avg. Vol
188,155
52-wk High
$152.55
52-wk Low
$106.83

Latest Key Developments (Source: Significant Developments)

Corsair Pharma And United Therapeutics Enter Into Strategic Collaboration To Advance Novel Treprostinil Prodrugs
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - United Therapeutics Corp ::CORSAIR PHARMA AND UNITED THERAPEUTICS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE NOVEL TREPROSTINIL PRODRUGS.UNITED THERAPEUTICS SAYS GRANTED EXCLUSIVE LICENSE TO CORSAIR'S INTELLECTUAL PROPERTY FOR DEVELOPMENT OF TREPROSTINIL PRODRUG FORMULATIONS.UNITED THERAPEUTICS CORP - MADE MINORITY EQUITY INVESTMENT IN CORSAIR THAT INCLUDES AN OPTION TO ACQUIRE REMAINING OUTSTANDING SHARES OF CORSAIR.UNITED THERAPEUTICS SAYS UNDER TERMS OF LICENSE AGREEMENT, CORSAIR RECEIVED UPFRONT CONSIDERATION.UNITED THERAPEUTICS- CORSAIR IS ENTITLED TO ROYALTY PAYMENTS ON COMMERCIALIZATION OF TREPROSTINIL PRODRUG PRODUCTS BY CO COVERED BY CORSAIR'S PATENTS.  Full Article

STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Steadymed Ltd ::‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​.‍INVALIDITY DECISION WILL PRECLUDE UNITED THERAPEUTICS FROM ASSERTING '393 PATENT PRIOR TO STEADYMED'S LAUNCH OF ITS TREVYENT PRODUCT​.‍FDA REGULATIONS REQUIRE THAT UNITED THERAPEUTICS "PROMPTLY NOTIFY FDA TO…WITHDRAW PATENT" FROM FDA'S "ORANGE BOOK."​.  Full Article

United Therapeutics Corp reports third quarter 2017 financial results
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - United Therapeutics Corp :United Therapeutics Corporation reports third quarter 2017 financial results.Q3 revenue $446 million versus I/B/E/S view $426.4 million.United Therapeutics Corp - qtrly ‍SHR $6.27​.United Therapeutics Corp - qtrly ‍non-GAAP earnings per diluted share $4.69​.Qtrly ‍non-GAAP earnings, per diluted share $4.69​.Q3 earnings per share view $3.87 -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system
Monday, 23 Oct 2017 

Oct 23 (Reuters) - United Therapeutics Corp :United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system.United Therapeutics Corp - ‍launch of TD-300/A planned for mid-2018​.  Full Article

United Therapeutics Corp Q2 income per diluted share $4.39
Thursday, 28 Jul 2016 

United Therapeutics Corp Qtrly Non : United Therapeutics Corp qtrly net income, per diluted share $4.39 . Q2 earnings per share view $3.22, revenue view $395.0 million -- Thomson Reuters I/B/E/S . United Therapeutics Corporation reports second quarter 2016 financial results . Q2 revenue $400 million versus I/B/E/S view $395 million .Gaap earnings, per diluted share $4.55.  Full Article

BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin

* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: (https://bit.ly/2E6Hb6r) Further company coverage: